Causes of Dry Eyes & Meibomianitis
Treating Dry eye & MGD before cataract surgery can reduce negative symptoms and improve quality of vision after surgery.
What is MGD?
MGD (Meibomian Gland Dysfunction) occurs when there are blockages or structural damage that inhibits the natural production of protective oils from the meibomian glands located in our eyelids. These blockages can disrupt the tear film and cause ocular surface disease, which can negatively affect surgical outcomes.
In 86% of cases, MGD is a root cause of dry eyes disease.
Symptoms of Dry Eyes & Meibomianitis
Treatment of Dry Eyes & Meibomian Gland Dysfunction
Treatment of Dry Eyes & Meibomian Gland Dysfunction can improve Cataract Surgery outcomes
New clinical guidelines recommend treating Dry Eye & MGD before surgery, even if there are no dry eye symptoms.
How is Dry eye & MGD identified?
MGD assessment can be easily performed during a routine eye exam. Your doctor will evaluate your meibomian gland function and structure and may give you a symptom questionnaire.
MGD is a disease and treatment before surgery is recommended to reduce dry eyes.
LipiFlow® is the favoured pre-operative MGD procedural treatment for over 80% of the ASCRS Cornea Clinical Committee members.
Treat MGD with LipiFlow®
Gland blockages are removed and gland function is restored with LipiFlow® . Through advances in the application of Vectored Thermal Pulsation (VTPTM) technology, LipiFlow® is a non-invasive 12-minute treatment administered in your doctor’s practice.
In a study of patients undergoing cataract surgery LipiFlow® significantly reduced dry eye symptoms.
LipiFlow® treated patients had almost 2x reduction in dry eye symptoms
In a study of 200 patients, LipiFlow® significantly improved meibomian gland function and reduced dry eye symptoms.
Untreated patients had 40% increase in dry eye symptoms after surgery
LipiFlow® increases mean gland function by 3-fold on average with one 12-minute treatment
LipiFlow® reduced mean dry eye symptom scores by over 50% for sustained symptom relief
Frequently asked questions
LipiFlow® helps optimize the ocular surface by treating meibomian gland dysfunction, which is one of the main causes of dry eye disease and ocular surface disease. Treating MGD before surgery can help reduce post-operative symptoms and increase quality of vision after surgery.
New clinical guidelines recommend being screened and treated for MGD even in the absence of symptoms in order to achieve optimal surgical outcomes.
The LipiFlow® Activator is placed under your eyelid. It is shaped to protect the delicate structure of the eye. Once in place, the device heats the meibomian glands and applies gentle massage to improve meibomian gland function.
The LipiFlow® procedure lasts 12 minutes and treats both eyes at the same time.
The results of LipiFlow® treatment vary person to person. Clinical studies have shown sustained results lasting up to one year and sometimes longer.
One treatment is all it takes to achieve sustained and effective results. However, MGD is a chronic condition and requires ongoing management.
- Proven to optimize comfort, visual outcomes, and patient satisfaction after surgery
- Proven effective for treating Dry Eyes & MGD before cataract surgery and improving quality of vision after surgery
LipiFlow® treatment is available at
Dr Natasha Lim Eye Centre and
Novena Bladeless Cataract Surgery & Eye Specialist Centre